← Eichor
Study identifier: NCT05994690 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

CHIP-AML22/Master: An Open Label Complex Clinical Trial in Newly Diagnosed Pediatric de Novo AML Patients

Condition: Acute Myeloid Leukemia in Children  ·  Sponsor: Princess Maxima Center for Pediatric Oncology

PhasePhase 3
Planned participants905
Who can joinAll sexes, 1 Day to 18 Years
Healthy volunteersNo

About this study

The CHIP-AML22 Master protocol has the overall aim of increasing the cure rate in newly diagnosed pediatric de novo AML patients, while avoiding unnecessary toxicity.

This description comes directly from the study's public registry record.

Talk to the study team

Renske Benedictus  ·  +31889727272  ·  CHIP-AML22@prinsesmaximacentrum.nl

Always discuss trial participation with your own doctor first.

Locations (1)

Princess Máxima Center for pediatric oncologyUtrecht, Utrecht, NetherlandsRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05994690